Safety and efficacy of thioridazine as salvage therapy in indian patients with XDR-TB

Recent Patents on Anti-Infective Drug Discovery

Volumn 6, Issue 2, 2011, Pages 88-91

  Udwadia, Zarir F ^a   Sen, Tiyas ^a   Pinto, Lancelot M ^a  

^a P D HINDUJA NATIONAL HOSPITAL   (India)

Author keywords

Salvage drug; Thioridazine; XDR TB

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CAPREOMYCIN; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LINEZOLID; MOXIFLOXACIN; OFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; THIORIDAZINE;

ADOLESCENT; ADULT; ARTICLE; BACTERIAL STRAIN; BEDTIME DOSAGE; CASE REPORT; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; ECG ABNORMALITY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEMALE; HEART PALPITATION; HUMAN; INDIAN; MALE; MONOTHERAPY; MYCOBACTERIUM TUBERCULOSIS; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PNEUMOTHORAX; PRIORITY JOURNAL; RESPIRATORY FAILURE; SALVAGE THERAPY; SKIN BURNING SENSATION; SPUTUM SMEAR; SURVIVAL TIME; THORAX RADIOGRAPHY;

ADOLESCENT; ADULT; ANTITUBERCULAR AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; HUMANS; INDIA; MALE; MYCOBACTERIUM TUBERCULOSIS; SALVAGE THERAPY; THIORIDAZINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 79959935423     PISSN: 1574891X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489111796064614     Document Type: Article

References (11)

1. World Health Organization (2009) Global tuberculosis control: Surveillance, planning, financing. WHO report 2009. Geneva, World Health Organization (WHO/HTM/TB/2009).
2. World Health Organization. Anti-tuberculosis drug resistance in the world, Fourth Global Report, WHO, Geneva (WHO/HTM/TB/2008.394). Available at http://www.who.int/tb/publications/2008/drs_report4_26feb08.pdf.
3. Jain SRC, Rodrigues C, Mehta A, Udwadia ZF. High prevalence of XDR-TB from a tertiary hospital in India. Amer Thoracic Soc 2007 IntConf; San Francisco, CA, USA; 2007; 18-23: Abstract A510.
4. Balaji V, Daley P, Anand AA, Sudarsanam T, Michael JS, Sahni RD, et al. Risk factors for MDR and XDR-TB in a tertiary referral hospital in India. PLoS One 2010; 5(3):e9527.
5. Agrawal D, Udwadia ZF, Rodriguez C, Mehta A. Increasing incidence of fluoroquinolone-resistant Mycobacterium tuberculosis in Mumbai, India. Int J Tuberc Lung Dis 2009; 13(1): 79-83.
6. Amaral L, Martins M, Viveiros M, Molnar J, Kristiansen JE. Promising therapy of XDR-TB/MDR-TB with thioridazine an inhibitor of bacterial efflux pumps. Curr Drug Targets 2008 (9): 816-9.
7. Amaral L, Kristiansen JE, Abebe LS, Kristiansen JE, Abebe LS, Millett W. Inhibition of the respiration of multi-drug resistant clinical isolates of Mycobacterium tuberculosis by thioridazine: potential use for initial therapy of freshly diagnosed tuberculosis. J Antimicrob Chemother 1996; (6):1049-53.
8. van Soolingen D, Hernandez-Pando R, Orozco H, Aguilar D, Magis-Escurra C, Amaral L, et al. The antipsychotic thioridazine shows promising therapeutic activity in a mouse model of multidrug-resistant tuberculosis. PLoS One 2010; 5(9).
9. Amaral L, Boeree MJ, Gillespie SH, Udwadia ZF, van Soolingen D. Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now! Int J Antimicrob Agents 2010; 35(6): 524-6.
10. Abbate E, Vescoso M, Natiello M, Cufre M, Garcia A, Ambroggi M, et al. Tuberculosis extensamente resistente (XDR-TB) en Argentina: Aspectos destacbles epidemiologicos, bacteriologicos, terapeuticos y evolutivos, Revista Argentina de Medicina Respiratoria 1 2007; 19-25.
11. Amaral L, Molnar J. Potential therapy of XDR-TB with Thioridazine, a drug beyond patent protection but eligible for patent as "New Use". Recent Pat Antiinfect Drug Discov 2010; 5: 109-114.